Baculovirus displaying SARS-CoV-2 spike RBD promotes neutralizing antibody production in a mouse model.

ABSTRACT:

Background

There is always a need for a safe and efficient vaccine platform, especially when facing a pandemic such as COVID-19. Most of the SARS-CoV-2-based vaccines are based on the full spike protein, which is presented as a trimerized protein, and many viral vector vaccines express the spike protein into the host cells and do not display it on virus surfaces. However, the spike receptor-binding domain (RBD)-based vaccines are efficient and are currently under investigation and clinical trials.

Methodology

In this study, we are testing the efficacy of the RBD displayed on a baculovirus as a mean to formulate a safe and stable carrier to induce the immune system against SARS-CoV-2. Therefore, two pseudotyped baculoviruses were constructed to display the RBD, AcRBD-sfGFP-64

SUBMITTER: Wahba MA 

PROVIDER: S-EPMC9910779 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature